logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Malignant Neoplasm Of Breast

    FiltersReset Filters
    16 results

    • abraxane

      (Paclitaxel)
      Abraxis BioScience, LLC
      Usage: ABRAXANE is indicated for treating metastatic breast cancer after chemotherapy failure, as well as for first-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with carboplatin. It is also indicated for first-line treatment of metastatic pancreatic adenocarcinoma combined with gemcitabine.

    • anastrozole

      (Anastrozole Tablets)
      Avet Pharmaceuticals Inc
      Usage: Anastrozole is indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, first-line treatment of locally advanced or metastatic breast cancer (hormone receptor-positive or unknown), and second-line treatment for advanced breast cancer following tamoxifen therapy.

    • anastrozole

      (Anastrozole Tablets)
      Yiling Pharmaceutical, Inc.
      Usage: Anastrozole is indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for the first-line treatment of hormone receptor-positive or unknown locally advanced/metastatic breast cancer, and for second-line treatment in cases of disease progression after tamoxifen therapy.

    • arimidex

      (Anastrozole)
      ANI Pharmaceuticals, Inc.
      Usage: ARIMIDEX is indicated for adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for first-line and second-line treatment of hormone receptor-positive or unknown locally advanced and metastatic breast cancer, particularly after disease progression on tamoxifen therapy.

    • cerianna

      (FLUOROESTRADIOL F 18)
      GE Healthcare Inc.
      Usage: CERIANNA is indicated for detecting estrogen receptor-positive lesions in recurrent or metastatic breast cancer using positron emission tomography (PET) imaging, as an adjunct to tissue biopsy. It is not effective for imaging other receptors like HER2 and progesterone receptor. Biopsy is required to confirm cancer recurrence and ER status.

    • faslodex

      (Fulvestrant)
      AstraZeneca Pharmaceuticals LP
      Usage: FASLODEX is indicated for treating HR-positive, HER2-negative advanced breast cancer in postmenopausal women, either as monotherapy for untreated or progressing disease, or in combination with ribociclib, palbociclib, or abemaciclib following disease progression on prior endocrine therapy.

    • fulvestrant

      (fulvestrant)
      Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      Usage: Fulvestrant injection is indicated for treating hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women, both as monotherapy and in combination with ribociclib, palbociclib, or abemaciclib after previous endocrine therapy.

    • herceptin

      (Trastuzumab)
      Genentech, Inc.
      Usage: Herceptin is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer in combination with paclitaxel, or as a single agent after previous regimens. It is also used with cisplatin and capecitabine for HER2-positive metastatic gastric cancer. Patient selection should utilize an FDA-approved diagnostic.

    • ibrance

      (palbociclib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: IBRANCE is indicated for adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor or fulvestrant after disease progression, and with inavolisib and fulvestrant for endocrine-resistant, PIK3CA-mutated cases after adjuvant endocrine therapy.

    • ibrance

      (palbociclib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: IBRANCE is indicated for adult patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor or fulvestrant, and also with inavolisib and fulvestrant for endocrine-resistant, PIK3CA-mutated cases after recurrence post-adjuvant therapy.